{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:31:54Z","timestamp":1790976714031,"version":"4.1.0"},"reference-count":31,"publisher":"Japanese Society of Veterinary Science","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Vet. Med. Sci.","The Journal of Veterinary Medical Science"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1292\/jvms.12-0366","type":"journal-article","created":{"date-parts":[[2012,11,4]],"date-time":"2012-11-04T22:50:11Z","timestamp":1352069411000},"page":"349-354","source":"Crossref","is-referenced-by-count":20,"title":["A Potential Therapeutic Application of SET\/I2PP2A Inhibitor OP449 for Canine T-cell Lymphoma"],"prefix":"10.1292","volume":"75","author":[{"given":"Nobuyuki","family":"FUJIWARA","sequence":"first","affiliation":[{"name":"Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyoshi","family":"KAWASAKI","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"YABE","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale J.","family":"CHRISTENSEN","sequence":"additional","affiliation":[{"name":"Department of Medicine (Hematology), Duke University, Durham, NC, U.S.A."},{"name":"Oncotide Pharmaceuticals, Inc., Research Triangle Park, NC, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"VITEK","sequence":"additional","affiliation":[{"name":"Departments of Medicine (Neurology) and Neurobiology, Duke University, Durham, NC, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"MIZUNO","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"SATO","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"OHAMA","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"122","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2011.07.020"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Arnold, H. K. and Sears, R. C. 2008. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev. 27: 147&ndash;158.","DOI":"10.1007\/s10555-008-9128-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Boyce, K. L. and Kitchell, B. E. 2000. Treatment of canine lymphoma with COPLA\/LVP. J. Am. Anim. Hosp. Assoc. 36: 395&ndash;403.","DOI":"10.5326\/15473317-36-5-395"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Carlson, S. G., Eng, E., Kim, E. G., Perlman, E. J., Copeland, T. D. and Ballermann, B. J. 1998. Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms&rsquo; tumor. J. Am. Soc. Nephrol. 9: 1873&ndash;1880.","DOI":"10.1681\/ASN.V9101873"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1038\/nature05933"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2009.10.005"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-351072"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Christensen, D. J., Ohkubo, N., Oddo, J., Van, Kanegan, M. J., Neil, J., Li, F., Colton, C. A. and Vitek, M. P. 2011. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J. Immunol. 186: 2535&ndash;2542.","DOI":"10.4049\/jimmunol.1002847"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Crist&oacute;bal, I., Garcia-Orti, L., Cirauqui, C., Alonso, M. M., Calasanz, M. J. and Odero, M. D. 2011. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 25: 606&ndash;614.","DOI":"10.1038\/leu.2010.294"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.050542"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00150-8"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1892\/0891-6640(2002)016<0704:EOACPW>2.3.CO;2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Janssens, V., Goris, J. and Van, Hoof, C. 2005. PP2A: the expected tumor suppressor. Curr. Opin. Genet. Dev. 15: 34&ndash;41.","DOI":"10.1016\/j.gde.2004.12.004"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Keller, E. T., MacEwen, E. G., Rosenthal, R. C., Helfand, S. C. and Fox, L. E. 1993. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J. Vet. Intern. Med. 7: 289&ndash;295.","DOI":"10.1111\/j.1939-1676.1993.tb01021.x"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M709585200"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2001.7541"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Li, F. Q., Sempowski, G. D., McKenna, S. E., Laskowitz, D. T., Colton, C. A. and Vitek, M. P. 2006. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. J. Pharmacol. Exp. Ther. 318: 956&ndash;965.","DOI":"10.1124\/jpet.106.103671"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.06.009"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Marconato, L., Gelain, M. E. and Comazzi, S. 2012. The dog as a possible animal model for human non-Hodgkin lymphoma: <i>a review<\/i>. Hematol. Oncol. .","DOI":"10.1002\/hon.2017"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Neviani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B. W., Liu, S., Mao, H., Chang, J. S., Galietta, A., Uttam, A. and others 2005. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein. Cancer Cell 8: 355&ndash;368.","DOI":"10.1016\/j.ccr.2005.10.015"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.099788"},{"key":"22","unstructured":"22. Samanta, A. K., Chakraborty, S. N., Wang, Y., Kantarjian, H., Sun, X., Hood, J., Perrotti, D. and Arlinghaus, R. B. 2009. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 28: 1669&ndash;1681."},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M710530200"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.622"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2011.04.009"},{"key":"26","unstructured":"26. von, Lindern, M., van, Baal, S., Wiegant, J., Raap, A., Hagemeijer, A. and Grosveld, G. 1992. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3&rsquo; half to different genes: characterization of the set gene. Mol. Cell. Biol. 12: 3346&ndash;3355."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Westermarck, J. and Hahn, W. C. 2008. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol. Med. 14: 152&ndash;160.","DOI":"10.1016\/j.molmed.2008.02.001"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Willems, L., Tamburini, J., Chapuis, N., Lacombe, C., Mayeux, P. and Bouscary, D. 2012. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr. Oncol. Rep. 14: 129&ndash;138.","DOI":"10.1007\/s11912-012-0227-y"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Yang, Y., Huang, Q., Lu, Y., Li, X. and Huang, S. 2012. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J. Cell. Biochem. 113: 1314&ndash;1322.","DOI":"10.1002\/jcb.24003"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Zhang, Q., McCorkle, J. R., Novak, M., Yang, M. and Kaetzel, D. M. 2011. Metastasis suppressor function of NM23-H1 requires its 3&rsquo;-5&rsquo; exonuclease activity. Int. J. Cancer 128: 40&ndash;50.","DOI":"10.1002\/ijc.25307"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2009.01.035"}],"container-title":["Journal of Veterinary Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/75\/3\/75_12-0366\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T21:26:49Z","timestamp":1643578009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/75\/3\/75_12-0366\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1292\/jvms.12-0366","relation":{},"ISSN":["0916-7250","1347-7439"],"issn-type":[{"value":"0916-7250","type":"print"},{"value":"1347-7439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}